Literature DB >> 11334314

Glomerular growth under cyclosporine treatment in childhood nephrotic syndrome.

H J Jeong1, J H Kim, P K Kim, I J Choi.   

Abstract

BACKGROUND: Glomerular hypertrophy is important in children with idiopathic nephrotic syndrome in regard to diagnosis and pathogenesis. Moreover, glomerular growth may be altered by cyclosporine (CsA) treatment in these patients.
METHODS: Bowman's area (BA) and the glomerular tuft area (GA) of pre- and post-treatment biopsies was measured by morphometry in 47 children with idiopathic nephrotic syndrome (39 MCD and 8 FSGS) treated with CsA and low-dose prednisolone for up to 2 years.
RESULTS: BA and GA increased with age. The mean BA and GA were 1.2 times larger in FSGS than in MCD and the proportional increase was similar in both diseases after treatment. BA and GA decreased in 48.9% and 40.4% of cases after treatment, respectively, whereas tubulointerstitial lesion (TIL) developed in 27.7%. BA and GA decreased to 10.4% and 8.3%, respectively in children who developed TIL after treatment and the values were largely unchanged in those treated for more than 16 months.
CONCLUSIONS: Glomerular growth is hampered by CsA nephrotoxicity, which is a more common complication than TIL. The impairment of glomerular growth is related to the duration of treatment and the development of TIL, but not to age or diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334314

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Osteopontin expression and microvascular injury in cyclosporine nephrotoxicity.

Authors:  Beom Jin Lim; Pyung Kil Kim; Soon Won Hong; Hyeon Joo Jeong
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

2.  Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats.

Authors:  Ji Hong Kim; Yeon Hee Lee; Beom Jin Lim; Hyeon Joo Jeong; Pyung Kil Kim; Jae Il Shin
Journal:  Sci Rep       Date:  2016-03-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.